Loading
A phase 1/2 trial of RNK05047 in advanced solid tumours, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) is a phase 1/2 interventional study registered as NCT05487170 by Ranok Therapeutics (Hangzhou) Co., Ltd., with 32 participants planned, started 2022-07-12 and due to reach its primary completion in 2025-06-01. Interventions recorded: RNK05047.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ranok Therapeutics (Hangzhou), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ranok Therapeutics (Hangzhou) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/